Cat. No. 5029
Chemical Name: 2-Cyano-3-(4-hydroxyphenyl)-2-prope
Biological ActivityMonocarboxylic acid transport (MCT) inhibitor. Exhibits antitumoral and antiangiogenic activity in gliomas in vivo; decreases glycolytic metabolism, migration, and invasion in U251 cells. Enhances the effect of antitumor agent temozolomide (Cat No. 2706). Blocks lactate efflux from glioma cells and sensitizes cells to irradiation.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Miranda-Gonçalves et al (2013) Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro.Oncol. 15 172. PMID: 23258846.
Colen et al (2006) Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study. Neurosurgery 59 1313. PMID: 17277695.
Fang et al (2006) The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol.Pharmacol. 70 2108. PMID: 17000864.
Dimmer et al (2000) The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem.J. 350 219. PMID: 10926847.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses CHC from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: CHC, supplier, a-cyano-4-OH-cinnamate, alpha-cyano-4-OH-cinnamate, CHC, monocarboxylic, acid, monocarboxylate, transporters, MCT, inhibitors, inhibits, lactate, pyruvate, glycolytic, metabolism, gliomas, antiangiogenesis, antitumoral, ACCA, á-cyano-4-hydroxy-cinnamic, acid, Tocris Bioscience, Monocarboxylate Transporter Inhibitor products